Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration.
J N King, M P Maurer, B O Altmann, G A Strehlau
Index: Am. J. Vet. Res. 61(1) , 80-5, (2000)
Full Text: HTML
Abstract
To determine pharmacokinetics of clomipramine and its principle metabolite (desmethylclomipramine) in the plasma of dogs following single-dose and repeated-dose oral administration at various dosages.9 male and 9 female Beagles.Clomipramine was administered orally at a dose of 1, 2, or 4 mg/kg to 3 male and 3 female dogs, first as a single dose and then, after an interval of 14 days, twice daily for 10 days. Plasma clomipramine and desmethylclomipramine concentrations were measured by use of a gas chromatography with mass-selection method.Dose-related accumulation was detected following repeated-dose administration. Accumulation ratios after administration of clomipramine at dosages of 1, 2, and 4 mg/kg twice daily were 1.4, 1.6, and 3.8, respectively, for clomipramine and 2.1, 3.7, and 7.6, respectively, for desmethylclomipramine. Terminal half-life increased slightly (1.6-fold for clomipramine and 1.2-fold for desmethylclomipramine) with repeated-dose administration but remained short in all groups (< or = 4 hours). Steady state was reached within 4 days in all animals. Ratios of the areas under the concentration versus time curves from time 0 to 12 hours for clomipramine and desmethylclomipramine were 3.9, 3.1, and 1.5 after repeated administration at dosages of 1, 2, and 4 mg/kg every 12 hours, respectively. Areas under the concentration versus time curve, mean residence times, and terminal half-lives were not significantly different between male and female dogs.Repeated administration of clomipramine results in higher concentrations of clomipramine than desmethylclomipramine in dogs.
Related Compounds
Related Articles:
2000-09-01
[Eur. Neuropsychopharmacol. 10(5) , 401-5, (2000)]
1993-12-01
[J. Affect. Disord. 29(4) , 267-79, (1993)]
2000-04-01
[Ther. Drug Monit. 22(2) , 190-4, (2000)]
2001-04-01
[Prog. Neuropsychopharmacol. Biol. Psychiatry 25(3) , 519-33, (2001)]
1994-04-01
[Acta Psychiatr. Scand. 89(4) , 230-4, (1994)]